Clene Inc.'s (NASDAQ:CLNN) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Clene Inc.'s (NASDAQ:CLNN) future prospects. Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The US$56m market-cap company posted a loss in its most recent financial year of US$26m and a latest trailing-twelve-month loss of US$27m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is Clene's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

According to the 5 industry analysts covering Clene, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2027, before generating positive profits of US$62m in 2028. So, the company is predicted to breakeven approximately 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 71%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

We're not going to go through company-specific developments for Clene given that this is a high-level summary, though, bear in mind that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for Clene

Before we wrap up, there’s one issue worth mentioning. Clene currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

This article is not intended to be a comprehensive analysis on Clene, so if you are interested in understanding the company at a deeper level, take a look at Clene's company page on Simply Wall St. We've also put together a list of essential factors you should further examine:

1. Valuation: What is Clene worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Clene is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Clene’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.